On 8 October 2026, Essex Bio-Technology Limited executed an on-market buyback of 12,000 ordinary shares at HK$2.075 each, for a total consideration of HK$0.02 million, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange (HKEX).
The repurchase represents 0.00212% of the company’s 564.84 million issued shares (excluding treasury shares) outstanding prior to the transaction. All repurchased shares have been retained as treasury stock, increasing the treasury share balance to 2.18 million.
Following the buyback, Essex Bio-Technology’s issued share capital (excluding treasury shares) stands at 564.83 million, while total issued shares remain unchanged at 567.01 million.
The transaction was carried out under the share-repurchase mandate approved on 26 May 2026, which authorises buybacks of up to 56.70 million shares. Cumulative repurchases under this mandate now total 2.18 million shares, equivalent to 0.38% of the company’s issued share count at the mandate date, leaving approximately 54.52 million shares available for future repurchase.
In accordance with HKEX regulations, Essex Bio-Technology is subject to a 30-day moratorium—ending 7 November 2026—on issuing new shares or disposing of treasury shares following the latest repurchase.
Comments